The Technical Analyst
Better Therapeutics, Inc. [BTTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Better Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-22.50% $0.0062
America/New_York / 19 apr 2024 @ 15:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.338 mill |
| EPS: | -1.100 |
| P/E: | -0.0100 |
| Earnings Date: | Apr 22, 2024 |
| SharesOutstanding: | 54.52 mill |
| Avg Daily Volume: | 5.88 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0148 - 0.0272 ( +/- 338.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-09 | Perry David P | Buy | 839 895 | Common Stock |
| 2024-01-09 | Perry David P | Buy | 1 471 453 | Common Stock |
| 2023-12-18 | Perry David P | Buy | 3 750 | Common Stock |
| 2023-12-18 | Carmona Richard H | Buy | 3 750 | Common Stock |
| 2023-12-18 | Lavizzo-mourey Risa J | Buy | 3 750 | Common Stock |
| INSIDER POWER |
|---|
| 99.10 |
| Last 98 transactions |
| Buy: 15 006 415 | Sell: 72 086 |
Forecast:
16:00 - $0.0062
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0062
Forecast 2: 16:00 - $0.0062
Forecast 3: 16:00 - $0.0062
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0062 (-22.50% ) |
| Volume | 0.264 mill |
| Avg. Vol. | 5.88 mill |
| % of Avg. Vol | 4.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BTTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BTTX
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Latest Press Releases
2024-03-14 09:38:00 - Press Release
Better Therapeutics Announces It Will Seek Strategic Alternatives And Will Be Delisted From Nasdaq
San francisco--(business wire)---- $bttx #digitalhealth--better therapeutics, inc. (nasdaq: bttx) (the “company”) announced today that the company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the company. this decision was made at a special meeting of the board of directors on wednesday evening, march 13, 2024. further, as previously disclosed, the company's securities are subject to delisting from the nasdaq stock market u.
2024-03-05 09:25:00 - Press Release
Better Therapeutics Announces An Innovative Partnership With The American College Of Lifestyle Medicine To Expand Access To Aspyrerx Across 1,400 Federally Qualified Health Centers
San francisco--(business wire)---- $bttx #digitalhealth--better therapeutics, inc. (nasdaq: bttx), a pioneer in developing prescription digital therapeutics (pdts) for treating cardiometabolic diseases, today announced a major partnership with the american college of lifestyle medicine's (aclm) national training initiative (nti), aimed at improving diabetes outcomes in underserved communities across the united states. through this partnership, better therapeutics is committed to making one million prescriptions of its.
2024-03-04 09:25:00 - Press Release
Better Therapeutics Announces Acceptance Of Late Breaking Abstract For Its Aspyrerx Pivotal Trial 180 Day Outcomes And Participation At The 17th International Conference On Advanced Technologies & Treatments For Diabetes (attd)
San francisco--(business wire)---- $bttx #digitalhealth--better therapeutics, inc. (nasdaq: bttx), a pioneer in developing prescription digital therapeutics (pdts) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th international conference on advanced technologies & treatments for diabetes (attd), to be held from march 6 to 9, 2024, in florence, italy. attd serves as a premier international forum showca.
2024-03-01 09:00:00 - Press Release
Better Therapeutics And Biotricity Interviews To Air On The Redchip Small Stocks, Big Money(tm) Show On Bloomberg Tv
Orlando, fl / accesswire / march 1, 2024 / redchip companies will air interviews with better therapeutics, inc. (nasdaq:bttx) and biotricity, inc. (nasdaq:btcy) on the redchip small stocks, big money™ show, a sponsored program on bloomberg tv, this saturday, march 2, at 7 p.m. eastern time (et).
2024-02-20 09:25:00 - Press Release
Better Therapeutics Receives Fda Breakthrough Device Designation For Digital Therapeutic Platform Targeting Advanced Liver Disease
San francisco--(business wire)---- $bttx #digitalhealth--better therapeutics, inc. (nasdaq: bttx), a pioneer in developing prescription digital therapeutics (pdts) for treating cardiometabolic diseases, today announced that the u.s. food and drug administration (fda) has granted breakthrough device designation for its novel cognitive behavioral therapy (cbt) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (mash), formerly known as nash. breakthrough status is reserved for technol.
Latest News
2024-02-22 11:56:05 - Zacks Investment Research
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
2023-08-09 22:34:05 - Seeking Alpha
Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Keay Nakae - Chardan Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode.
2023-08-02 17:30:00 - Business Wire
Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 09, 2023. To access the conference call, please register at: https://re.
2023-07-11 08:57:21 - InvestorPlace
Why Is Better Therapeutics (BTTX) Stock Up 39% Today?
Better Therapeutics (NASDAQ: BTTX ) stock is taking off on Tuesday as investors react to approval from the FDA for a Type 2 diabetes treatment. This covers AspyreRx, which is a prescription-only digital therapeutic treatment for patients 18 and older with Type 2 diabetes.
2023-05-14 04:13:19 - Seeking Alpha
Better Therapeutics, Inc. (BTTX) Q1 2023 Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Mark Heinen - CFO Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Lucas Romanski - TD Cowen Keay Nakae - Chardan Keay Rahul Rakhit - LifeSci Capital Operator Good morning and thank you for standing by, and welcome to the Better Therapeutics' First Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
2023-04-06 13:42:29 - Zacks Investment Research
Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade
Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-11-14 22:27:07 - Seeking Alpha
Better Therapeutics, Inc. (BTTX) Q3 2022 - Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and Chief Executive Officer Mark Berman - Chief Medical Officer Diane Gómez-Thinnes - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Operator Good afternoon, and welcome to the Better Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
2022-08-14 06:34:06 - Seeking Alpha
Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call Participants Thomas Flaten – Lake Street Capital Rahul Rakhit – LifeSci Capital Keay Nakae – Chardan Operator Good morning, and welcome to the Better Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
2022-07-28 11:10:38 - InvestorPlace
Why Is Better Therapeutics (BTTX) Stock Up 27% Today?
Source: Minerva Studio / Shutterstock.com Better Therapeutics (NASDAQ: BTTX ) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2 diabetes.
2022-07-26 07:30:00 - Business Wire
Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics managemen